"Now that GLP-1 drugs have revolutionized how millions of Americans treat obesity and Type 2 diabetes, scientists are exploring the benefits of using the drugs for a host of other chronic diseases - many with few treatment options - such as heart failure, chronic liver disease, obstructive sleep apnea, and even substance use disorders. "Their role is now being understood to be much, much more fundamental to human health, and to promoting longevity and preventing chronic illness progression,""
"GLP-1 receptor agonists - sold under brand names like Ozempic and Mounjaro - were initially developed to treat diabetes. But instead of addressing biomarkers linked to certain disease outcomes, these drugs influence the central cardio-kidney metabolic process, Vaduganathan said. This overarching approach has made GLP-1 drugs the most effective and tolerable choice for most patients treating diabetes and obesity. It's also what makes it likely that they influence a number of closely related diseases."
GLP-1 receptor agonists, initially developed for diabetes, have become highly effective and tolerable therapies for obesity and Type 2 diabetes. These drugs act on a central cardio-kidney metabolic pathway rather than isolated biomarkers, enabling broader impact on related conditions. Researchers are investigating GLP-1s for heart failure, chronic liver disease, obstructive sleep apnea, and substance use disorders, among others. Excess weight and adiposity are identified as core drivers of disease onset and progression, and GLP-1s can rapidly target those drivers. Early clinical findings show benefits in heart failure with preserved ejection fraction and other chronic conditions.
Read at Harvard Gazette
Unable to calculate read time
Collection
[
|
...
]